Shots:
- Servier has entered into a definitive agreement to acquire Day One Biopharmaceuticals
- As per the deal, Servier will acquire Day One for $21.5/share in cash, representing the total equity value of ~$2.5B, with remaining shares acquired later via a second-step merger; closing expected in Q2’26
- Acquisition will strengthen Servier’s leadership in pediatric low-grade glioma & reinforces its oncology targeted therapy portfolio, expanding its pipeline from early-stage to P-III programs for adult & pediatric cancers with high unmet needs, in line with its 2030 ambition to deliver innovative treatments
Ref: Servier | Image: Day One | Press Release
Related News: Day One Biopharmaceuticals to Acquire Mersana Therapeutics for ~$285M
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
